The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions
- PMID: 7966591
- PMCID: PMC237265
- DOI: 10.1128/JVI.68.12.8017-8027.1994
The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions
Abstract
The proteolytic processing sites of the human immunodeficiency virus type 1 (HIV-1) Gag precursor are cleaved in a sequential manner by the viral protease. We investigated the factors that regulate sequential processing. When full-length Gag protein was digested with recombinant HIV-1 protease in vitro, four of the five major processing sites in Gag were cleaved at rates that differ by as much as 400-fold. Three of these four processing sites were cleaved independently of the others. The CA/p2 site, however, was cleaved approximately 20-fold faster when the adjacent downstream p2/NC site was blocked from cleavage or when the p2 domain of Gag was deleted. These results suggest that the presence of a C-terminal p2 tail on processing intermediates slows cleavage at the upstream CA/p2 site. We also found that lower pH selectively accelerated cleavage of the CA/p2 processing site in the full-length precursor and as a peptide primarily by a sequence-based mechanism rather than by a change in protein conformation. Deletion of the p2 domain of Gag results in released virions that are less infectious despite the presence of the processed final products of Gag. These findings suggest that the p2 domain of HIV-1 Gag regulates the rate of cleavage at the CA/p2 processing site during sequential processing in vitro and in infected cells and that p2 may function in the proper assembly of virions.
Similar articles
-
Site-directed mutagenesis of the P2 region of the Rous sarcoma virus gag gene: effects on Gag polyprotein processing.Virology. 1994 Aug 15;203(1):20-8. doi: 10.1006/viro.1994.1450. Virology. 1994. PMID: 8030280
-
The human immunodeficiency virus type 1 capsid p2 domain confers sensitivity to the cyclophilin-binding drug SDZ NIM 811.J Virol. 1996 Sep;70(9):5751-7. doi: 10.1128/JVI.70.9.5751-5757.1996. J Virol. 1996. PMID: 8709190 Free PMC article.
-
Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle.J Virol. 1997 Oct;71(10):7312-7. doi: 10.1128/JVI.71.10.7312-7317.1997. J Virol. 1997. PMID: 9311808 Free PMC article.
-
Deletion mutagenesis within the dimerization initiation site of human immunodeficiency virus type 1 results in delayed processing of the p2 peptide from precursor proteins.J Virol. 1999 Jul;73(7):6147-51. doi: 10.1128/JVI.73.7.6147-6151.1999. J Virol. 1999. PMID: 10364374 Free PMC article.
-
Characterization of human immunodeficiency virus type 1 Pr160 gag-pol mutants with truncations downstream of the protease domain.Virology. 2004 Nov 10;329(1):180-8. doi: 10.1016/j.virol.2004.08.010. Virology. 2004. PMID: 15476885
Cited by
-
Dominant Negative MA-CA Fusion Protein Is Incorporated into HIV-1 Cores and Inhibits Nuclear Entry of Viral Preintegration Complexes.J Virol. 2019 Oct 15;93(21):e01118-19. doi: 10.1128/JVI.01118-19. Print 2019 Nov 1. J Virol. 2019. PMID: 31413124 Free PMC article.
-
Crystal structure of an FIV/HIV chimeric protease complexed with the broad-based inhibitor, TL-3.Retrovirology. 2007 Jan 9;4:1. doi: 10.1186/1742-4690-4-1. Retrovirology. 2007. PMID: 17212810 Free PMC article.
-
Comparison of human immunodeficiency virus type 1 Pr55(Gag) and Pr160(Gag-pol) processing intermediates that accumulate in primary and transformed cells treated with peptidic and nonpeptidic protease inhibitors.Antimicrob Agents Chemother. 2000 May;44(5):1397-403. doi: 10.1128/AAC.44.5.1397-1403.2000. Antimicrob Agents Chemother. 2000. PMID: 10770790 Free PMC article.
-
Hydrogen/deuterium exchange analysis of HIV-1 capsid assembly and maturation.Structure. 2010 Nov 10;18(11):1483-91. doi: 10.1016/j.str.2010.08.016. Structure. 2010. PMID: 21070947 Free PMC article.
-
Design and characterization of an HIV-specific ribonuclease zymogen.AIDS Res Hum Retroviruses. 2008 Nov;24(11):1357-63. doi: 10.1089/aid.2008.0146. AIDS Res Hum Retroviruses. 2008. PMID: 19025416 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
